Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

NCT07383506 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT07383506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07383506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 23, 2026
Completion date
August 31, 2029
Enrollment
90 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, adult, endometrial cancer, her2-low breast cancer, hr positive/her-2 negative breast cancer, pik3ca mutations